| abstract |
The present invention relates to an ICOS-binding protein or an antigen-binding portion thereof, wherein the ICOS-binding protein or an antigen-binding portion thereof is human ICOS, and a method for treating cancer, infectious disease and/or sepsis with the ICOS-binding protein or an antigen-binding portion thereof agonist and does not induce complement, ADCC or CDC when contacted with T cells in vivo. In addition, the ICOS binding proteins of the invention, or antigen-binding portions thereof, are capable of activating T cells upon contact with said T cells; stimulating T cell proliferation upon contact with said T cells; and/or upon contact with said T cells Induce cytokine production. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of the following: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and/or SEQ ID NO:6. |